OVERCOMING CURRENT CHALLENGES OF CAR-T CELL IMMUNOTHERAPY FOR T-ALL LEUKEMIA WITH OPTIMIZED CAR CONSTRUCTS (TRUCS) AND UNIVERSAL, OFF-THE-SHELF, EFFECTOR ALLOGENEIC T CELLS